Biochemistry of Corona Virus: An Overveiw
Nwaogwugwu Joel Caleb *
Department of Chemistry, College of Art and Sciences, Prairie View A&M University, TX, USA.
Victor Chukwubuike Nwankwo
Department of Chemistry, College of Art and Sciences, Prairie View A&M University, TX, USA.
Nweke Celestine Chimaobi
Department of Biochemistry, Abia State University Uturu, Nigeria.
Ugoaghalam Uche James
Department of Computer Information System, College of Engineering Technology, Prairie View A&M University, TX, USA.
Uchenna Samuel Igwe
GEI Consultants Inc 5646 Milton St #500, Dallas, TX 75206, USA.
Aguwamba Chinedu
Department of Biochemistry, Clifford University, Owerrinta, Nigeria.
Faith Nwokoma
Department Electrical Engineering, Prairie View A&M University, TX, USA.
*Author to whom correspondence should be addressed.
Abstract
Coronaviruses forma large family of respiratory viruses having positive (+ve)-stranded RNA (C0V). Their names are derived from the crown-like shape that is present on their them (surface). The new viral strain SARS-CoV-2 was first discovered in Wuhan, China, in December 2019. Even though this virus can spread via airborne, direct, and indirect contact, the most typical way of infection transmission is through droplets. Like the other coronaviruses in the same family, it can causeeverything from minor flu-like symptoms like; cold, sore throat, cough, and fever, to very seriousones like; pneumonia and breathing difficulties. It also has the potential to be fatal. The primary constituents make up the coronavirus. For instance, the positive-stranded RNA molecule that the host cell will translate is carried by the endoplasm, cell membrane, and outer globular protein. The transit of substances into and out of the cell is regulated by the cell membrane and membrane protein. One or more of them include the pointed glycoprotein, envelope small membrane protein, hemagglutinin esterase, nucleoprotein, and genomic RNA. The second coronavirus that causes severe acute respiratory syndrome is the reason for the ongoing coronavirus disease epidemic known as covid-19 pandemic or coronavirus pandemic (SARS-COV-2). It was originally discovered in December 2019 in Wuhan, China. The World Health Organization (WHO) classified the outbreak as a pandemic and a public health emergency of global concern in January 2020 and March 2020, respectively. As of March 7th, 2021, COVID-19, one of the deadliest pandemics in recorded history, had been linked to over 2.59 million fatalities and over 11.7 million confirmed cases. Being vaccination is one of the steps you may take to protect yourself and others from getting infected with COVID-19. Protection from COVID-19 is essential since it can cause severe illness or death in some persons. It takes all the tools at our disposal to stop a pandemic. You can reduce your risk of getting sick or spreading the disease to others by taking additional precautions like wearing masks and avoiding social situations. Combining the COVID-19 vaccine with following the CDC’s recommendations for safeguarding both you and others will provide the best defense against the virus.
Keywords: COVID-19, SARS-CoV-1, vaccine, Hemagglutin esterase
How to Cite
Downloads
References
Hui DSEIA, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J Infect Dis. 2020; 91:264-6.
Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130-7.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y et al. Early transmission dynamics in Wuhan, China of novel coronavirus–infected, pneumonia. N Engl J Med. 2020;382(13):1199-207.
Harding A, Lanese N. The 12 deadliest viruses on earth. Livescience. 2020;7:12.
Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H et al. The origin Yan Yan, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Mil. Med Resour. 2020;7:11.
Zhang MQ, Wang XH, Chen YL, Zhao KL, Cai YQ, An CL et al. Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing. Chin J Tuberc Respir Dis. 2020;43:13.
Ceraolo C, Giorgi FM. Genomic variance of the 2019-nCoV coronavirus. Journals Medical Virology. J Med Virol. 2020;92(5):522-8.
Cannizzaro E, Ramaci T, Cirrincione L, Plescia F. Work-related stress, physiopathological mechanisms, and the influence of environmental genetic factors. International journals environment resources. Public Health. 2019;16:4031.
Decaro N, Tidona C, Darai G. Gammacoronavirus. In Coronaviridae. The springer index of viruses. Springer. 2015;403-13.
de Groot RJ, Baker SC, Baric R, Enjuanes L, Gorbalenya AE, Holmes KV et al. Family Coronaviridae. Rep Int Committee Taxon Viruses. Ninth. 2015:806-28.
Geller C, Varbanov M, Duval RE. Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies. Viruses. 2012;4(11):3044-68.
Lotfi M, Hamblin MR, Rezaei N. COVID-19: transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta Int J. Clin Chem. 2020;508:254-66.
Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy. 2008;63(11):1455-63.
Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med. 2021;174(1):69-79.
Tellier R, Li Y, Cowling BJ, Tang JW. Recognition of aerosol transmission of infectious agents: A commentary. BMC Infect Dis. 2019;19(1):101.
Van DN, Bushmaker T, Morris DH, Holbrook M, Gamble A, Williamson B et al. Aerosol and surface stability of HCoV-19 (SARS CoV-2) compared to SARS-CoV-1. Medical. 2020;19:25-40.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(10223):507-13.
Zhonghua L, Xing B, Xue ZZ. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chin J Epidemiol. 2020;41:145-51.
Won J, Lee S, Park M, Kim TY, Park MG, Choi BY et al. Development of a laboratory-safe and low-cost detection protocol for SARS-CoV-2 of the coronavirus disease 2019 (COVID-19). Neurobiology. 2020;17:121.
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381-5.
Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem. 2017;60(5):1648-61.
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295 (15):4773-9.
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P et al. In vitro antiviral activity and projection of Optimizied dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infect Dis. 2020;10:450-500.
Xu X, Han M, Li T, Sun W, Wang D, Fu B et al. Effective treatment of severe COVID-19 patients with tocilizumab. Medical diseases. 2020;15:150-200.
Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of sars-cov–a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226-36.
Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: A potential approach for coronavirus infection therapy? Clin Sci (Lond). 2020; 134(5):543-5.
Furukawa NW, Brooks JT, Sobel J. Evidence supporting transmission of severe acute respiratory syndrome coronavirus 2 while presymptomatic or asymptomatic. Emerg Infect Dis. 2020;26(7).
Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. N Engl J Med. 2020;383(18):1757-66.
Forgie S, Marrie TJ. Healthcare-associated atypical pneumonia. Semin Respir Crit Care Med. 2009;30(1):67-85.
Ren W, Sun H, Chen J, Sun S, Zhao R, Gao G et al. Recombinant SAR-CoV-2 spike SI-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates. Vaccine. 2020; 95:210-300.
Abdul-Rasool S, Fielding BC. Understanding human coronavirus HCoV-NL63. Open Virol J. 2010;4:76-84.
Eschner K. We’re still not sure where the COVID-19 really came from. Popul Sci. Archived from the original. 2020; 8:337-555.
Tirotta E, Carbajal KS, Schaumburg CS, Whitman L, Lane TE. Cell replacement therapies to promote remyelination in a viral model of demyelination. J Neuroimmunol. 2010;224(1-2):101-07.
Johansen P, Storni T, Rettig L, Qiu Z, Der-Sarkissian A, Smith KA et al. Antigen kinetics determines immune reactivity. Proc. National Academic Sciences. 2017;105(13):5189-94.
Shiu EYC, Leung NHL, Cowling BJ, Tada H, Nohara A, Kawashiri MA. Controversy around airborne versus droplet transmission of respiratory viruses: implication for infection prevention. Curr Opin Infect Dis. 2019;32(4):372-9.
Otter JA, Donskey C, Yezli S, Douthwaite S, Goldenberg SD, Weber DJ. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. J Hosp Infect. 2016;92(3):235-50.
Lee SA, Grinshpun SA, Reponen T. Respiratory performance offered by N95 respirators and surgical masks: human subject evaluation with NaCl aerosol representing bacterial and viral particle size range. Ann Occup Hyg. 2008;52(3):177-85.
Chellamani KP, Veerasubramanian D, Vignesh Balaji RS. Surgical face masks: manufacturing methods and classification. Industrial Resourses. 2013;2:6.
Grant OC, Montgomery DW, Ito K, Woods RJ. Analysis of the SARS-CoV-2 spike protein glycan shield. Implic Immune Recognit. 2020;9:2754.
Kilinc FS. A review of isolation gowns in healthcare: fabric and gown properties. J Eng Fiber Fabr. 2015;10(3):180-90.
Tang T, Bidon M, Jaimes JA, Whittaker GR, Daniel S. Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antiviral Res. 2020;178:104792.
Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet. 2020;395(10228):931-4.
Callaway E. The race for coronavirus vaccines: A graphical guide. Nature. 2020;580(7805):576-7.
Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020; 52(4):583-9.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8.
Zang R, Gomez Castro MFG, McCune BT, Zeng Q, Rothlauf PW, Sonnek NM et al. TMPRSS2 AND TMPRSS4 Promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci. Immunol. 2020; 5(47):20-5.
Colbert JD, Cruz FM, Rock KL. Cross-presentation of exogenous antigens on MHC I molecules. Curr Opin Immunol. 2020;64:1-8.